Treatment of Multiple Sclerosis with Anti-CD20 Therapies: Experience of the Mohammed V Military Teaching Hospital
Sarah Slimani, Manal Bourrouk, Kaoutar Hjiej, Hajar Belghacham, Ihsane Hmamouchi, Mohamed Amine Mnaili, Youssouf Ben Moh & Ahmed bourazza · Asian Journal of Research and Reports in Neurology · 2026
Background: Anti-CD20 monoclonal antibodies, including rituximab (RTX) and ocrelizumab (OCR), have markedly improved the management of multiple sclerosis (MS) by reducing inflammatory disease activity. However, local evidence regarding their effectiveness and safety in real-world...
Open access
Research Article
10.9734/ajorrin/2026/v9i1187